I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I'm dealing with the effects of it ...

In recent weeks there has been a buzz around a new treatment breakthrough: benralizumab, which in a study published in the ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulm ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said.

A dipstick urine test and a mobile app may help predict disease exacerbations in COPD patients as much as a week in advance, ...

Patients with COPD who have mucus plugs identified via CT scans are associated with greater risks for acute exacerbations of their disease.

British drug maker GSK plc (GSK, GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data ...